-
Mashup Score: 0Initiating selexipag within 12 months of PAH diagnosis may reduce hospitalizations, costs - 2 year(s) ago
NASHVILLE, Tenn. — Initiation of oral selexipag within 12 months of pulmonary arterial hypertension diagnosis may reduce all-cause hospitalizations and overall medical costs, according to a new analysis.“One of the key take-home findings is that earlier initiation of PAH combination therapy can deliver improvement in outcomes, particularly reduction in all-cause
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Selexipag improves outcomes in PAH-associated connective tissue disease in real-world study - 2 year(s) ago
SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.At the American Thoracic Society International Conference, Sean Gaine, MD, with the National Pulmonary Hypertension Unit at Mater Misericordiae Hospital in Dublin, Ireland, and colleagues reported patient
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
#ICYMI: Presented at #ATS2022: #Selexipag initiation improved outcomes in patients with #PAH associated with connective tissue disease. @CardiologyToday https://t.co/spvneMVsEk
-
-
Mashup Score: 1Selexipag improves outcomes in PAH-associated connective tissue disease in real-world study - 2 year(s) ago
SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.At the American Thoracic Society International Conference, Sean Gaine, MD, with the National Pulmonary Hypertension Unit at Mater Misericordiae Hospital in Dublin, Ireland, and colleagues reported patient
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
New real-world data demonstrate #selexipag initiation improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease. Read more below #ATS2022 #PAH @CardiologyToday https://t.co/tClOzpNQt9
-
New real-world data demonstrate #selexipag initiation improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease. Read more below #ATS2022 #PAH @CardiologyToday https://t.co/3FOmk4Lb6l
-
-
Mashup Score: 0FDA approves selexipag for IV use in adults with PAH - 3 year(s) ago
The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy. Selexipag (Uptravi, Janssen) for IV use will allow patients to avoid short-term interruptions and stay on their therapy, as uninterrupted treatment is important for patients with PAH, according to a company press release.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
#FDA approves #selexipag for intravenous use in adults with #pulmonaryhypertension @CardiologyToday #PAH https://t.co/sMYbBnw7CZ
-
-
Mashup Score: 0FDA approves selexipag for IV use in adults with PAH - 3 year(s) ago
The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy. Selexipag (Uptravi, Janssen) for IV use will allow patients to avoid short-term interruptions and stay on their therapy, as uninterrupted treatment is important for patients with PAH, according to a company press release.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
#FDA approves #selexipag for intravenous use in adults with #pulmonaryhypertension @CardiologyToday #PAH https://t.co/sMYbBnw7CZ
-
-
Mashup Score: 4FDA approves selexipag for IV use in adults with PAH - 3 year(s) ago
The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy. Selexipag (Uptravi, Janssen) for IV use will allow patients to avoid short-term interruptions and stay on their therapy, as uninterrupted treatment is important for patients with PAH, according to a company press release.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDA approves #selexipag for intravenous use in adults with #pulmonaryhypertension @CardiologyToday #PAH https://t.co/SQhor5L7N3
-
#FDA approves #selexipag for intravenous use in adults with #pulmonaryhypertension @CardiologyToday #PAH https://t.co/QtaUdi5COG
-
-
Mashup Score: 0
Registry of patients with pulmonary arterial hypertension (PAH) treated with selexipag provides insights into real-world dosing regimens and outcomes.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
SPHERE Registry Provides Snapshot of #Selexipag to Treat #PAH in the Real World: https://t.co/RDzGEuQlpH https://t.co/oinNi9DcRQ
-
-
Mashup Score: 1Hospitalizations Lower in Pulmonary Arterial Hypertension Patients Receiving Selexipag or Treprostinil - Pulmonology Advisor - 3 year(s) ago
Real-world hospitalization rates in patients taking selexipag or treprostinil for PAH showed that selexipag is directly associated with lower hospitalization rates.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
Real-world #hospitalization rates in patients taking #selexipag or #treprostinil for #PAH showed that selexipag is associated with lower hospitalization rates. Read More: https://t.co/TcsVYVTa6C
-
Presented at #CHEST2022: Initiation of #selexipag within 12 months of pulmonary artery hypertension diagnosis may reduce #hospitalizations and medical costs, according to a new analysis @Journal_CHEST #PAH https://t.co/MMbDg4onYX